Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome

To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue therapy in patients with antisynthetase syndrome and progressive interstitial lung disease (ASS-ILD). Multicentre observational retrospective longitudinal study of a cohort of patients with ASS-ILD that started treatmen...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis research & therapy 2024-06, Vol.26 (1), p.122-12, Article 122
Main Authors: Narváez, Javier, Cañadillas, Elena, Castellví, Iván, Alegre, Juan José, Vincens-Zygmunt, Vanesa, Bermudo, Guadalupe, Vidal-Montal, Paola, Molina Molina, María, Nolla, Joan Miquel
Format: Article
Language:English
Subjects:
Adult
Aged
Analysis
Antisynthetase syndrome
Progressive interstitial lung disease
Treatment
Rituximab
Care and treatment
Corticosteroids
Development and progression
Diagnosis
Disease Progression
Dosage and administration
Drug therapy
Female
Humans
Longitudinal Studies
Lung diseases
Lung diseases, Interstitial
Lung Diseases, Interstitial - drug therapy
Male
Medical research
Medicine, Experimental
Middle Aged
Myositis - complications
Myositis - drug therapy
Patient outcomes
Prednisone
Pulmonary function tests
Respiratory Function Tests - methods
Retrospective Studies
Rituximab - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue therapy in patients with antisynthetase syndrome and progressive interstitial lung disease (ASS-ILD). Multicentre observational retrospective longitudinal study of a cohort of patients with ASS-ILD that started treatment with RTX due to recurrent or ongoing progressive ILD despite therapy with glucocorticoids and immunosuppressants. Twenty-eight patients were analyzed. Examining the entire study population, before treatment with RTX the mean decline in %pFVC and %pDLCO from the ASS-ILD diagnosis to the initiation of RTX treatment (T0) was -6.44% and -14.85%, respectively. After six months of treatment, RTX reversed the decline in pulmonary function test (PFT) parameters: ∆%pFVC +6.29% (95% CI: -10.07 to 2.51; p=0.002 compared to T0) and ∆%pDLCO +6.15% (95% CI: -10.86 to -1.43; p=0.013). Twenty-four patients completed one year of therapy and 22 two years, maintaining the response in PFT: ∆%pFVC: +9.93% (95% CI: -15.61 to -4.25; p=0.002) and ∆%pDLCO: +7.66% (95% CI: -11.67 to -3.65; p
ISSN:1478-6362
1478-6354
1478-6362
DOI:10.1186/s13075-024-03353-2